1020174-06-4

Basic information

• Product Name: Ethyl 4-chloro-2-iodobenzoate
• Synonyms: Ethyl 4-chloro-2-iodobenzoate;4-Chloro-2-iodo-benzoic acid ethyl ester;Benzoic acid, 4-chloro-2-iodo-, ethyl ester
• CAS NO: 1020174-06-4
• Molecular Formula: C₉H₈ClIO₂
• Molecular Weight: 310.51609
• Product Categories: Acids & Esters;Chlorine Compounds;Iodine Compounds
• Mol File: 1020174-06-4.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Ethyl 4-chloro-2-iodobenzoate(CAS DataBase Reference)
• NIST Chemistry Reference: Ethyl 4-chloro-2-iodobenzoate(1020174-06-4)
• EPA Substance Registry System: Ethyl 4-chloro-2-iodobenzoate(1020174-06-4)

Safety Data

• Hazardous Substances Data: 1020174-06-4(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Ethyl 4-chloro-2-iodobenzoate is used as a reactant for the preparation of heterocyclic urea derivatives, which are known as kinase inhibitors. Kinase inhibitors play a crucial role in the regulation of cellular processes, including cell signaling and regulation of the cell cycle. By targeting specific kinases, these inhibitors can potentially be used in the development of therapeutic treatments for various diseases, particularly cancer.

Upstream product

• 64-17-5 ethanol 
• 13421-13-1 4-chloro-2-iodobenzoic acid 
• 13421-00-6 5-chloro-2-iodo-benzoic acid 
• 75-03-6 ethyl iodide 

Relevant articles and documents

Critical Ligand and Salt Effects in Organomagnesiate-Promoted 3,3-Disubstituted Phthalides Synthesis from 2-Iodobenzoate Derivatives

Phthalides, also called isobenzofuranones, are widespread in many biologically active compounds and natural products. To date, most of their synthetic routes are non-convergent. Herein we report a convergent route using a metal halogen exchange (MHE) strategy. Indeed MHE of easily available 2-iodobenzoate derivatives, using the bimetallic organomagnesiate complex (rac)-(BIPHEN)BuMgLi, where (rac)-BIPHEN is (rac)-5,5′,6,6′-tetramethyl-3,3′-di-t-butyl-1,1′-biphenyl-2,2′-diol, followed by addition of a ketone which lead to an intramolecular cyclisation, and the formation of a series of diverse 3,3-disubstituted isobenzofuranones in good yield. Among the several MHE agents investigated, (rac)-(BIPHEN)BuMgLi was the only one to make such a process possible with full tolerance of various reactive functional substituents useful for subsequent transformations. The synthetic pathway to access the magnesiate has been found to play a prominent role in its reactivity. Therefore, the bimetallic magnesiate complex has been characterized by solution-state 1H, 7Li and 1H DOSY NMR experiments.

One-Pot C-H Arylation/Lactamization Cascade Reaction of Free Benzylamines

An efficient method has been developed for the synthesis of seven-membered biaryl lactams involving Pd-catalyzed, native amine-directed, ortho-arylation of benzylamines followed by in situ lactamization. This cascade sequence is enabled by the use of 2-iodobenzoates, which facilitates C-H arylation from the free amine under conditions that typically require an improved directing group approach. This reaction is characterized by a broad substrate scope with good functional group tolerance. The need for an ester versus carboxylic acid-functionalized coupling partner is also explored, as is the potential for synthesizing eight-membered biaryl lactams. Various applications are also investigated, including access to the aza-brassinolide core.

INDOLINONE ANALOGUES

The present invention encompasses compounds of general formula (I) wherein the groups R1 to R4, A1 and A2 have the meanings given in the claims and in the specification. The compounds of the invention are suitable for the treatment of diseases characterized by excessive or abnormal cell proliferation pharmaceutical preparations containing such compounds and their uses as a medicament.

INDOLINONE ANALOGUES AS BRD4 INHIBITORS

The present invention encompasses compounds of general formula (I) wherein the groups R1 to R4, A1 and A2 have the meanings given in the claims and in the specification. The compounds of the invention are suitable for the treatment of diseases characterized by excessive or abnormal cell proliferation pharmaceutical preparations containing such compounds and their uses as a medicament.